Major adverse cardiovascular events
Major adverse cardiovascular events (MACE) is a clinical metric used to capture serious cardiovascular outcomes in a single composite endpoint.
Major adverse cardiovascular events (MACE) is a clinical metric used to capture serious cardiovascular outcomes in a single composite endpoint. Although the exact components can vary by study, MACE commonly includes events such as myocardial infarction, stroke, and cardiovascular death, and in some settings may also incorporate all-cause mortality or other ischemic outcomes. It is widely used in cardiovascular research because it provides a standardized way to measure overall event burden across populations with cardiovascular disease, acute coronary syndrome, heart failure, diabetes, obesity, atrial fibrillation, and related conditions.
As a composite endpoint, MACE is not a biological molecule or therapeutic target itself, but a trial and cohort outcome used to quantify risk reduction, prognosis, and treatment effectiveness. In modern clinical research, MACE is frequently assessed in studies of antithrombotic therapy, glucose-lowering agents, lipid-lowering treatment, vaccines, and risk prediction models, often alongside hazard ratio, propensity score matching, Cox proportional hazards model, and other epidemiologic methods. Its interpretation depends on the population studied and on the specific event definitions used for myocardial infarction, ischemic stroke, cardiovascular mortality, and related endpoints.
Where the papers sit
13 papers from the last 6 months study major adverse cardiovascular events directly · updated from PubMed 8 Oct 2026
Study type 2 clinical trials · 7 observational · 2 human data · 2 unclassified
Themes 3 themes · 1 new direction
-
Cardiovascular Outcomes Across Conditions
Cardiovascular risk is being characterized across heart failure, acute coronary syndrome, atrial fibrillation, Sjögren's disease, cancer therapy, and breast cancer survivorship. Stroke, heart failure, bleeding, and cardiovascular mortality recur as major endpoints. Machine-learning prediction and registry-based hazard estimates complement studies of social and inflammatory risk. The cluster remains focused on identifying high-risk patients rather than a single therapeutic direction.
6 papers · 46.2%
-
Type 2 Diabetes Cardiovascular Risk
Cardiovascular prevention is being linked to weight, inflammation, metabolic disease, and improved risk prediction. Tirzepatide and weight loss are associated with lower predicted or observed atherosclerotic risk, although weight-related benefits may partially rebound. Blood-based DNA methylation models add short-term stratification for people with type 2 diabetes. Colchicine, coronary microcalcification, and RSV vaccination broaden prevention beyond glucose control, without a single established strategy.
5 papers · 38.5%
-
Aortic Valve Outcome Tracking
Aortic valve intervention is being evaluated through longitudinal outcome tracking, with hospitalization, stroke, and myocardial infarction as recurring endpoints. SwissTAVI registry data provide the main framework for assessing trends after transcatheter aortic valve implantation. Electronic health record retrieval and large language models are being tested to identify cardiovascular events more efficiently. The shared direction is toward scalable, data-driven surveillance of post-procedural outcomes.
2 papers · 15.4%
Major adverse cardiovascular events become a target for validating automated clinical-outcome retrieval
The cardiovascular event cohorts of patients treated with immune checkpoint inhibitors and undergoing transcatheter aortic valve replacement use major adverse cardiovascular events not as an endpoint for estimating treatment effects or prognosis, but as a clinical label whose ascertainment is itself being tested. The study compares ICD codes, problem lists, primary diagnoses, and a large-language-model workflow with manual chart adjudication, making MACE a benchmark for measuring the accuracy of automated medical-record retrieval rather than merely an outcome to be counted or predicted. 42595369Aug
Papers
The 13 papers from the last 6 months that study major adverse cardiovascular events directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Cardiovascular Outcomes Across Conditions (6)
- Neighborhood Contemporary Redlining and Racial Mortgage Lending Bias and Cardiovascular Outcomes in Women With Breast Cancer. Journal of the American Heart Association · 9 Sept 2026 PMID 42714450
- Survival and predictors of major adverse cardiovascular events among patients with acute coronary syndrome in Ethiopia: a retrospective cohort study. BMJ open · 24 Jul 2026 PMID 42498465
- Impact of Age on Bleeding, Stroke, and Mortality in Edoxaban-Treated Patients with Atrial Fibrillation: Results from the ETAF-TR Registry. Drugs & aging · 15 Jul 2026 PMID 42455491
- Predicting major adverse cardiovascular and cerebrovascular events in chronic heart failure: a machine learning study. Annals of medicine · 13 Jun 2026 PMID 42286995
- Major adverse cardiovascular events in Sjögren's disease: incidence, associated factors, and impact on mortality in a prospective multicenter cohort. Rheumatology international · 1 Jun 2026 PMID 42223667
- Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. European heart journal · 27 May 2026 PMID 42199067
Type 2 Diabetes Cardiovascular Risk (5)
- Influence of low-dose colchicine on coronary microcalcification activity in patients with diffuse coronary artery disease undergoing coronary artery bypass grafting: protocol for single-centre randomised open-label blinded-endpoint trial (the COL-CABG trial). BMJ open · 15 Sept 2026 PMID 42744364
- Weight Loss Improves Predicted 10-Year MACE and Type 2 Diabetes Risk, but Benefits Partially Rebound at 1 Year. Obesity (Silver Spring, Md.) · 23 Aug 2026 PMID 42634098
- Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ (Clinical research ed.) · 5 Aug 2026 PMID 42556854
- Effectiveness of the adjuvanted RSVPreF3 vaccine in preventing major adverse cardiovascular events and severe exacerbations of chronic obstructive pulmonary disease and asthma among US adults aged ≥60 years. Chest · 23 Jul 2026 PMID 42492842
- Blood-Based DNA Methylation Models Improve Short-term Cardiovascular Risk Stratification in Individuals With Type 2 Diabetes. Diabetes care · 16 Jul 2026 PMID 42461785
Aortic Valve Outcome Tracking (2)
- Diagnostic accuracy of electronic medical record retrieval methods and a large language model for identifying cardiovascular events: a multisite retrospective validation study in a medical system in the United States. BMJ open · 13 Aug 2026 PMID 42595369
- Longitudinal Trends and Outcomes in Transcatheter Aortic Valve Implantation: a report from the SwissTAVI Registry. Cardiovascular intervention and therapeutics · 15 Jun 2026 PMID 42298270
By study type
Clinical trials (2)
- Influence of low-dose colchicine on coronary microcalcification activity in patients with diffuse coronary artery disease undergoing coronary artery bypass grafting: protocol for single-centre randomised open-label blinded-endpoint trial (the COL-CABG trial). BMJ open · 15 Sept 2026 PMID 42744364
- Weight Loss Improves Predicted 10-Year MACE and Type 2 Diabetes Risk, but Benefits Partially Rebound at 1 Year. Obesity (Silver Spring, Md.) · 23 Aug 2026 PMID 42634098
Observational studies and case reports (7)
- Diagnostic accuracy of electronic medical record retrieval methods and a large language model for identifying cardiovascular events: a multisite retrospective validation study in a medical system in the United States. BMJ open · 13 Aug 2026 PMID 42595369
- Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ (Clinical research ed.) · 5 Aug 2026 PMID 42556854
- Survival and predictors of major adverse cardiovascular events among patients with acute coronary syndrome in Ethiopia: a retrospective cohort study. BMJ open · 24 Jul 2026 PMID 42498465
- Impact of Age on Bleeding, Stroke, and Mortality in Edoxaban-Treated Patients with Atrial Fibrillation: Results from the ETAF-TR Registry. Drugs & aging · 15 Jul 2026 PMID 42455491
- Predicting major adverse cardiovascular and cerebrovascular events in chronic heart failure: a machine learning study. Annals of medicine · 13 Jun 2026 PMID 42286995
- Major adverse cardiovascular events in Sjögren's disease: incidence, associated factors, and impact on mortality in a prospective multicenter cohort. Rheumatology international · 1 Jun 2026 PMID 42223667
- Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. European heart journal · 27 May 2026 PMID 42199067
Human data, design not indexed (2)
- Neighborhood Contemporary Redlining and Racial Mortgage Lending Bias and Cardiovascular Outcomes in Women With Breast Cancer. Journal of the American Heart Association · 9 Sept 2026 PMID 42714450
- Blood-Based DNA Methylation Models Improve Short-term Cardiovascular Risk Stratification in Individuals With Type 2 Diabetes. Diabetes care · 16 Jul 2026 PMID 42461785
Unclassified: not yet indexed with MeSH (2)
- Effectiveness of the adjuvanted RSVPreF3 vaccine in preventing major adverse cardiovascular events and severe exacerbations of chronic obstructive pulmonary disease and asthma among US adults aged ≥60 years. Chest · 23 Jul 2026 PMID 42492842
- Longitudinal Trends and Outcomes in Transcatheter Aortic Valve Implantation: a report from the SwissTAVI Registry. Cardiovascular intervention and therapeutics · 15 Jun 2026 PMID 42298270
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-08-07. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.